Vitamin K2 Containing Food Product – Patent application no. 09/850,804 (“ex-Unilver”) approved in USA September 17th 2012

NattoPharma ASA is pleased to announce that our patent application no. 09/850,804 (“ex-Unilvere”) re. “Vitamin K2 Containing Food product” has been approved and issued in USA by the United States Patent and Trade Office. This will strengthen NattoPharma's IPR and commercial platform in USA significantly. The patent will give NattoPharma a broad coverage on the use of menaquinones (vitamin K2) in the preparation of a food product (including dietary supplement) for maintaining, optimizing, strengthening or promoting cardiovascular health.

"The approval of the patent represents a milestone for NattoPharma and our partners in the US market. This will strengthen NattoPharma's global IPR-platform and improve our competitive position in USA within the food supplement market as well as the functional food market" says Dr. Hogne Vik, CEO of NattoPharma.

About NattoPharma ASA
NattoPharma ASA, Norway is the exclusive international supplier of MenaQ7, the natural vitamin K2. NattoPharma has entered into a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the exciting marketplace for functional food and health food supplements.

For more information, please visit www.nattopharma.com

About MenaQ7
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bascillus subtilis natto. This process has the capacity of producing the highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.

For more information on the health benefits of MenaQ7, please visit www.menaq7.com  

For more information, please contact:
CEO Dr. Hogne Vik
Phone: +47 975 35 326 

Tags: